4 years ago

Actimed Therapeutics Secures £2.5M to Advance Muscle Wasting Disorder Treatments

  • Actimed Therapeutics, a UK-based clinical stage company developing treatments for muscle wasting disorders, has closed its extended Seed B financing round, raising over £2.5 million

  • The funds will be used to advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia

  • Actimed also retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting may impact survival.

      • ProblemHealthcare

      "Cachexia, a wasting disease that accompanies cancer and other serious chronic illnesses, is associated with significant morbidity and mortality. There is currently no effective treatment for cachexia, leaving patients with a poor prognosis and limited quality of life. "

      Solution

      "Actimed Therapeutics is developing a novel treatment for cachexia, S-pindolol (ACM-001.1), that targets multiple pathways that drive the disease. The company has generated promising proof of concept Phase II clinical data in cachexia patients and is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC)."

      Covered on